INC Research (NASDAQ: INCR) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare INC Research to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.
Risk & Volatility
INC Research has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, INC Research’s competitors have a beta of 1.51, meaning that their average stock price is 51% more volatile than the S&P 500.
99.5% of INC Research shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 0.2% of INC Research shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent recommendations for INC Research and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|INC Research Competitors||564||2517||6753||133||2.65|
INC Research currently has a consensus price target of $49.88, indicating a potential upside of 23.15%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.86%. Given INC Research’s higher possible upside, equities analysts plainly believe INC Research is more favorable than its competitors.
This table compares INC Research and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|INC Research Competitors||-4,626.94%||-476.54%||-43.26%|
Valuation and Earnings
This table compares INC Research and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|INC Research||$1.61 billion||$112.63 million||-71.05|
|INC Research Competitors||$217.40 million||-$39.57 million||-61.96|
INC Research has higher revenue and earnings than its competitors. INC Research is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
INC Research beats its competitors on 7 of the 13 factors compared.
About INC Research
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.